Randomized Phase II trial of Neoadjuvant weekly Nab-paclitaxel followed by FEC compared with Docetaxel followed by FEC for early breast cancer

Trial Profile

Randomized Phase II trial of Neoadjuvant weekly Nab-paclitaxel followed by FEC compared with Docetaxel followed by FEC for early breast cancer

Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 17 May 2016

At a glance

  • Drugs Paclitaxel (Primary) ; Cyclophosphamide; Docetaxel; Epirubicin; Fluorouracil
  • Indications Breast cancer
  • Focus Therapeutic Use
  • Most Recent Events

    • 27 Sep 2015 Results presented at the ASCO - Breast Cancer Symposium 2015
    • 03 Jun 2011 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top